Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | TSPO | P30536 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882280 | 0.84 | CYP1A2 (0.38) | CYP1A2GAAHPGDUTS2RPTGS2 | |
| SCHEMBL13233715 | 0.80 | GAA (0.42) | CYP1A2GAAHPGDUTS2RPTGS2 | |
| SCHEMBL2882093 | 0.79 | OPRM1 (0.36) | CYP1A2GAAHPGDUTS2RPTGS2 | |
| SCHEMBL2879925 | 0.75 | COMT (0.38) | CYP1A2GAAHPGDPTGS2LMNA | |
| SCHEMBL21095529 | 0.58 | HTR6 (0.48) | CYP1A2GAAHPGDPTGS2LMNA | |
| SCHEMBL23736202 | 0.57 | SCN2A (0.56) | GAAHPGD | |
| SCHEMBL12392439 | 0.56 | MAP2 (0.49) | CYP1A2HPGDPTGS2SIRT1 | |
| SCHEMBL23758279 | 0.56 | HRH1 (0.60) | GAA | |
| SCHEMBL2344704 | 0.55 | MAP2 (0.52) | SIRT1 | |
| SCHEMBL2344421 | 0.55 | HPGD (1.00) | CYP1A2GAAHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168097-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | claimed |
| EP-1898928-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2007002458-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168097-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | RNGTT, POLR1E, RTF1 | CYP1A2 585/4885GAA 565/4885HPGD 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.